PLX

Biotechnology PLX Uncategorized

Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy

Jan 30, 2026

protalix,-secarna-in-agreement-to-develop-rare-kidney-disorder-therapies

Biotechnology PLX Uncategorized

Protalix, Secarna in agreement to develop rare kidney disorder therapies

Dec 17, 2025

Comments Mohammed Haneefa Nizamudeen Protalix BioTherapeutics (PLX) and Secarna Pharmaceuticals will work together to develop...